Name | No. | For Patients with | Purpose |
---|---|---|---|
innovaTV 301 / ENGOT cx12 | 19-02 | Second or Third-Line Recurrent or Metastatic Cervical Cancer |
Tisotumab vedotin is an antibody-drug conjugate targeting tissue factor (TF). Preliminary safety and |
DSSG Group: Gynaecological
ENGOT-en15/ KEYNOTE-C93-00/ GOG-3064
Name | No. | For Patients with | Purpose |
---|---|---|---|
ENGOT-en15/ KEYNOTE-C93-00/ GOG-3064 | 22-02 | Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting |
The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy. |
ENGOT-ov65 / KEYNOTE-B96
Name | No. | For Patients with | Purpose |
---|---|---|---|
ENGOT-ov65 / KEYNOTE-B96 | 22-03 | Platinum resistant Recurrent Ovarian Cancer (PROT) Patients can have epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1-2 prior lines of systemic therapy, including at least 1 prior platinum-based therapy with ≥4 cycles in first line. |
The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival. |
OVHIPEC-2
Name | No. | For Patients with | Purpose |
---|---|---|---|
OVHIPEC-2 | 20-07 | Stage III Epithelial Ovarian Cancer |
The objective of this study is to prove that treatment with primary cytoreductive surgery in combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive surgery without HIPEC (standard arm) |